Emcure Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,820 Cr +24.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
EP

Emcure Pharmaceuticals Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Emcure Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,363Cr
+20.4% YoY
+4.1% QoQ
Net profit
₹231Cr
+48.1% YoY
−8% QoQ
Margin
21%
+3 pp YoY
0 pp QoQ
Price₹1,863
Market cap₹37.2K Cr
P/E39.3

The short version

Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.

From Emcure Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years.
  • Domestic business is expected to grow in the high single-digits to low double digits, with Emcure targeting to outgrow the industry, driven by in-house R&D and strategic in-licensing.
  • International markets (Europe and Canada) anticipate low-teens compounded growth, supported by strong ramp-up in products like Amphotericin B.
  • Emerging markets, including ARV and non-ARV segments, are expected to grow at a healthy double-digit rate.
  • Amphotericin B, recently launched in parts of Europe, offers significant growth potential across 23 countries with expected growth from next year onward.

2 more points from Emcure Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.
  • The company plans to maintain this capex intensity to support growth and capacity expansion.
  • Focus on building strong in-house capacities, considered second only to innovators for certain high-volume products.
  • Strategic investments include expanding manufacturing capacities at Sanand and Pune sites to service diverse markets.
  • Emphasis on technology-driven R&D pipeline and collaborations, including partnerships with academia for biologics innovation.

2 more points from Emcure Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights related to growth and capacity include: - Emcure has built significant capacity for high-volume products, considered second only to innovators. - The company is capitalizing on a large European market opportunity, e.g., Amphotericin B with a market size exceeding EUR 100 million. - They are launching products across 23 countries with gradual ramp-up expected to contribute to growth. - Robust product pipeline and favorable market launches support future order intake.

2 more points from Emcure Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Emcure Pharmaceuticals Ltd Q3 FY26 results — key figures

Emcure Pharmaceuticals Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue2,3631,963+20.4%2,270+4.1%
Operating profit (EBITDA)493355+38.9%475+3.8%
Operating margin21%18%+3 pp21%0 pp
Profit before tax314230+36.5%341-7.9%
Net profit (PAT)231156+48.1%251-8%
EPS (₹)12.168.11+49.9%12.84-5.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.8K Cr, net profit ₹325 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Emcure Pharmaceuticals Ltd Q3 FY26 results?

Emcure aims for a low to mid-teens compounded growth rate in overall sales over the next 3 to 5 years. Emcure aims for a low to mid-teens compounded annual revenue growth over the next 3 to 5 years, driven by both domestic and international markets.

What is Emcure Pharmaceuticals Ltd share price analysis?

Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.

Is Emcure Pharmaceuticals Ltd planning capital expenditure?

Emcure expects gross block additions of INR 300-400 crores per year over the next 2-3 years, excluding acquisitions.

Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.